ReviewHerz2026
T-TEER-interventional repair of tricuspid regurgitation.
Review in Herz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe tricuspid regurgitation (TR) is a common right-sided valvular disease associated with a substantially increased risk of morbidity, hospitalization, and mortality. Transcatheter tricuspid edge-to-edge repair (T-TEER) is a minimally invasive therapy for patients with severe, symptomatic TR at high surgical risk. By approximating the valve leaflets, T‑TEER reduces regurgitant volume, improves right heart hemodynamics, and interrupts the progressive cycle of right ventricular dilation and worsening TR. Studies and registry data show that approximately 81-88% of patients treated with T‑TEER achieve a reduction of TR to moderate or less, accompanied by sustained improvements in functional status, quality of life, right heart remodeling, and reductions in heart failure-related hospitalizations. Early analyses also suggest beneficial effects on renal and hepatic function. Therefore, T‑TEER represents a safe and effective treatment option for patients with severe TR who previously had limited therapeutic options.
Indexed as
Identifiers
41758333What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.